Cline Scientific AB ("Cline" eller "Bolaget") har genom en egenutvecklad och patenterad gradienttekn...
Frånvaron av nya spellanseringar under år 2022 har resulterat i en successivt minskad omsättning sed...
With strong clinical evidence to treat the growing problem of Sports Related Concussions (SRCs), Pol...
NOSIUM har inlett 2023 med full fart och kommunicerat ett flertal spännande nyheter.
Qlosr Group växte intäkterna med 75 procent till 145 mkr i Q4:an och överträffade sitt omsättningsmå...
Omsättningen faller drivet av försenade leveranser i USA.
Redeye comments on SDS’s Q4 results, which came in line with preliminary figures and well below our ...
Cost headwinds persist, share issue strengthens cash position 3.
Redeye retains its positive view on Efecte, following a Q4 report with high growth from new sales bo...
Redeye provides an update in relation to RLS’ Q4 2022 report.
41% organic sales growth, adj. EBITA margin 5% First report using IFRS affects goodwill and leasing ...
Finepart publicerade den 28 februari 2023 bolagets delårsrapport för det fjärde kvartalet år 2022.
Share down 20% today despite limited changes to outlook We expect positive FCF ex.
We cut '23e-'24e EBITDA by 3-6% Financial targets still achievable Positive outcomes in public and p...
Redeye ceases its current coverage of Isofol Medical due to the end of the contractual period.
Redeye comments on the progress of the phase I trial of Lipisense and the 2023 rights issue, which r...
Redeye comments on Fluoguide’s Q4 2022 report as we enter a catalyst-rich 2023e for the company.
Redeye provides a research update following Penneo’s Q4 2022 report.
Hedged against further rate hikes Plenty of project completions in 2023 Sector-high earnings growth ...
Redeye provides a research update after Nexstim's H2 report, which came in slightly below our projec...
